MedTrace Logo

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

NCT02535416 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.

Conditions

  • Healthy

Interventions

DRUG

ARC-520

DRUG

cetirizine

DRUG

diphenhydramine

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535416 on ClinicalTrials.gov